120 related articles for article (PubMed ID: 3126272)
21. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
Hoeldtke RD; Cilmi KM; Mattis-Graves K
Clin Pharmacol Ther; 1984 Sep; 36(3):302-6. PubMed ID: 6432398
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic studies of oral L-threo-3,4-dihydroxyphenylserine in normal subjects and patients with familial amyloid polyneuropathy.
Suzuki T; Higa S; Sakoda S; Ueji M; Hayashi A; Takaba Y; Nakajima A
Eur J Clin Pharmacol; 1982; 23(5):463-8. PubMed ID: 6818040
[TBL] [Abstract][Full Text] [Related]
23. Memory effect of DL-threo-3,4-dihydroxyphenylserine (DOPS) in human Korsakoff's disease.
Langlais PJ; Mair RG; Whalen PJ; McCourt W; McEntee WJ
Psychopharmacology (Berl); 1988; 95(2):250-4. PubMed ID: 3137605
[TBL] [Abstract][Full Text] [Related]
24. [The effect of L-threo-DOPS on P-300 in parkinsonism].
Yokota J; Itoh T; Imai H; Narabayashi H
Rinsho Shinkeigaku; 1990 May; 30(5):499-504. PubMed ID: 2119267
[TBL] [Abstract][Full Text] [Related]
25. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
Goldstein DS; Holmes C; Sewell L; Pechnik S; Kopin IJ
J Clin Pharmacol; 2011 Jan; 51(1):66-74. PubMed ID: 20220040
[TBL] [Abstract][Full Text] [Related]
26. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
Man in 't Veld AJ; Boomsma F; van den Meiracker AH; Julien C; Lenders J; Schalekamp MA
J Hypertens Suppl; 1988 Dec; 6(4):S547-9. PubMed ID: 3149290
[TBL] [Abstract][Full Text] [Related]
27. Effect of long-term L-threo-3,4-dihydroxyphenylserine administration on alpha 2-adrenergic receptors in platelet membranes in neurologic disorders.
Azuma T; Suzuki T; Sakoda S; Mizuno R; Tsujino S; Kobayashi T; Kishimoto S; Hiraga T; Matsubara T; Yoshida S
Acta Neurol Scand; 1991 Jul; 84(1):46-50. PubMed ID: 1656690
[TBL] [Abstract][Full Text] [Related]
28. Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats.
Araki H; Tanaka C; Fujiwara H; Nakamura M; Ohmura I
J Pharm Pharmacol; 1981 Dec; 33(12):772-7. PubMed ID: 6121848
[TBL] [Abstract][Full Text] [Related]
29. Analgesic effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in patients with chronic pain.
Takagi H; Harima A
Eur Neuropsychopharmacol; 1996 Mar; 6(1):43-7. PubMed ID: 8866937
[TBL] [Abstract][Full Text] [Related]
30. [Pure akinesia presenting with antecollis].
Ota S; Tsuchiya K
No To Shinkei; 2005 Oct; 57(10):893-8. PubMed ID: 16277235
[TBL] [Abstract][Full Text] [Related]
31. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
Sakoda S; Suzuki T; Higa S; Ueji M; Kishimoto S; Matsumoto M; Yoneda S
Eur Neurol; 1985; 24(5):330-4. PubMed ID: 3932074
[TBL] [Abstract][Full Text] [Related]
32. Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy.
Suzuki T; Higa S; Tsuge I; Sakoda S; Hayashi A; Yamamura Y; Takaba Y; Nakajima A
Eur J Clin Pharmacol; 1980 Jun; 17(6):429-35. PubMed ID: 6772451
[TBL] [Abstract][Full Text] [Related]
33. Clinical effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
Akizawa T; Koshikawa S; Iida N; Marumo F; Akiba T; Kawaguchi Y; Imada A; Yamazaki C; Suzuki M; Tubakihara Y
Nephron; 2002 Apr; 90(4):384-90. PubMed ID: 11961396
[TBL] [Abstract][Full Text] [Related]
34. Midodrine hydrochloride and L-threo-3,4-dihydroxy-phenylserine preserve cerebral blood flow in hemodialysis patients with orthostatic hypotension.
Fujisaki K; Kanai H; Hirakata H; Nakamura S; Koga Y; Hattori F; Iida M
Ther Apher Dial; 2007 Feb; 11(1):49-55. PubMed ID: 17309575
[TBL] [Abstract][Full Text] [Related]
35. [Development of L-threo-DOPS, a norepinephrine precursor amino acid].
Katsube J; Narabayashi H; Hayashi A; Tanaka C; Suzuki T
Yakugaku Zasshi; 1994 Nov; 114(11):823-46. PubMed ID: 7853146
[TBL] [Abstract][Full Text] [Related]
36. [Mechanism of the development of akinesia in Parkinson's disease --with reference to L-threo-DOPS therapy].
Narabayashi H
No To Shinkei; 1983 Nov; 35(11):1057-63. PubMed ID: 6362685
[No Abstract] [Full Text] [Related]
37. Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia.
Narabayashi H; Kondo T; Yokochi F; Nagatsu T
Adv Neurol; 1987; 45():593-602. PubMed ID: 3103397
[No Abstract] [Full Text] [Related]
38. Enzymatic decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat heart.
Ohmura I; Inagaki C; Araki H; Tanaka C
Jpn J Pharmacol; 1978 Oct; 28(5):747-53. PubMed ID: 31501
[TBL] [Abstract][Full Text] [Related]
39. Amelioration of frozen gait by tandospirone, a serotonin 1A agonist, in a patient with pure akinesia developing resistance to L-threo-3,4-dihydroxyphenylserine.
Miyata S; Hamamura T; Yoshinaga J; Nakamura Y; Imamura T; Hikiji A; Kuroda S
Clin Neuropharmacol; 2001; 24(4):232-4. PubMed ID: 11479395
[TBL] [Abstract][Full Text] [Related]
40. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
Tohgi H; Abe T; Takahashi S
J Neural Transm Park Dis Dement Sect; 1993; 5(1):27-34. PubMed ID: 8439390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
